12/3/2009

Javelin Pharmaceuticals filed a new-drug application to the FDA for Dyloject, a drug designed to manage acute moderate-to-severe pain in adults. The treatment contains diclofenac sodium, a commonly prescribed nonsteroidal anti-inflammatory drug.

Related Summaries